Flexion started at buy by Benchmark

Benchmark says Zilretta can be ‘best-in-class,’ starts Flexion at Buy. As previously reported, Benchmark analyst Bruce Jackson initiated Flexion Therapeutics with a Buy rating and $39 price target, citing his belief that Zilretta can emerge as a “best-in-class” therapy for treating osteoarthritis knee pain. He sees peak sales potential in excess of $750M for the drug, he tells investors in his initiation note.

https://bit.ly/2tDEmHv